The estimated Net Worth of Kevin James Sullivan is at least $6.1 Million dollars as of 31 August 2016. Kevin Sullivan owns over 1,000 units of Penumbra Inc stock worth over $5,957,827 and over the last 9 years Kevin sold PEN stock worth over $140,760.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Kevin Sullivan PEN stock SEC Form 4 insiders trading
Kevin has made over 2 trades of the Penumbra Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently Kevin sold 1,000 units of PEN stock worth $70,380 on 31 August 2016.
The largest trade Kevin's ever made was selling 1,000 units of Penumbra Inc stock on 31 August 2016 worth over $70,380. On average, Kevin trades about 500 units every 0 days since 2016. As of 31 August 2016 Kevin still owns at least 29,449 units of Penumbra Inc stock.
You can see the complete history of Kevin Sullivan stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Kevin Sullivan's mailing address?
Kevin's mailing address filed with the SEC is ONE PENUMBRA PLACE, 1351 HARBOR BAY PARKWAY, ALAMEDA, CA, 94502.
Insiders trading at Penumbra Inc
Over the last 9 years, insiders at Penumbra Inc have traded over $197,637,326 worth of Penumbra Inc stock and bought 700 units worth $109,480 . The most active insiders traders include Adam Elsesser, Arani Bose, and James Robert Pray. On average, Penumbra Inc executives and independent directors trade stock every 9 days with the average trade being worth of $2,030,383. The most recent stock trade was executed by Harpreet Grewal on 4 September 2024, trading 782 units of PEN stock currently worth $159,614.
What does Penumbra Inc do?
penumbra is a specialty interventional therapies company that develops and markets innovative medical devices to treat challenging medical conditions with significant unmet clinical needs. we design our therapies to provide our specialist physician customers with improved clinical outcomes through faster and safer procedures at significant overall cost savings to the healthcare system. today we have over 1,000 employees with sales operations in north america, europe, australia and asia.
What does Penumbra Inc's logo look like?
Complete history of Kevin Sullivan stock trades at Penumbra Inc
Penumbra Inc executives and stock owners
Penumbra Inc executives and other stock owners filed with the SEC include:
-
Johanna Roberts,
Executive Vice President, General Counsel, Secretary -
Maggie Yuen,
Chief Financial Officer -
Adam Elsesser,
Chairman of the Board, Chief Executive Officer -
Lynn Rothman,
Executive Vice President, Chief Business Officer -
Maggie S. Yuen,
Chief Financial Officer -
James Pray,
President, International -
Arani Bose,
Chief Innovator, Director -
Johanna Roberts,
Exec. VP, Gen. Counsel & Sec. -
Lambert Shiu,
Chief Accounting Officer -
Janet Leeds,
Independent Director -
Surbhi Sarna,
Independent Director -
Adam Elsesser,
Co-Founder, Chairman, Pres & CEO -
Harpreet Grewal,
Independent Director -
Bridget O'Rourke,
Independent Director -
Thomas Wilder,
Independent Director -
Don Kassing,
Presiding Independent Director -
Lambert Shiu,
Chief Accounting Officer -
Gita Barry,
Exec. VP & GM of Immersive Healthcare -
Ben Tompkins,
Exec. VP of Devel. -
Shruthi Narayan,
Director of Marketing - Vascular -
Dr. Arani Bose M.D.,
Co-Founder & Director -
Jee Hamlyn-Harris,
Investor Relations Officer -
Corey L. Teigen M.D.,
Chief Scientific Officer -
Ben Sorci,
Exec. VP of Operations -
Kevin James Sullivan,
Director -
Robert D. Evans,
EVP, Gen. Counsel & Secretary -
Daniel Donen Davis,
President, North America -
Sridhar Kosaraju,
President -
Walter Charles Wang,
Director